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Abstract
Background: Neuropsychiatric disorders are present in up to 90 % of patients with Tuberous Sclerosis Complex
(TSC), and represent an important issue for families. Autism Spectrum Disorder (ASD) is the most common
neurobehavioral disease, affecting up to 61 % of patients. The aims of this study were: 1) to assess the prevalence
of ASD in a TSC population; 2) to describe the severity of ASD; 3) to identify potential risk factors associated with
the development of ASD in TSC patients.
Methods: We selected 42 individuals over age 4 years with a definite diagnosis of TSC and followed at a TSC clinic
in Northern Italy. We collected and reported clinical and genetic data, as well as cognitive level, for each of them.
We administered the Social Communication Questionnaire (SCQ) as a reliable screening tool for ASD, and
performed comparisons between the average scores and each clinical and genetic feature.
Results: Seventeen out of 42 patients (40.5 %) had a score at the SCQ suggestive of ASD (≥15 points). When
calculated for each cognitive level category, the average SCQ score tended to be progressively higher in patients
with a worse cognitive level, and the number of pathological SCQ scores increased with worsening of intellectual
disability. With respect to ASD severity, the scores were equally distributed, indicating that the degree of ASD in
TSC patients may have a large variability. By comparing the average SCQ scores with the clinical features, we found
statistically significant correlations with epilepsy, seizure onset before age one year, spasms, mutations in TSC2,
cognitive level, sleep disorders, and other psychiatric problems, but not with seizure frequency, tubers localization
and gender.
Conclusions: Our study showed a prevalence of ASD of 40.5 %, confirming the higher risk for this disorder in
patients with TSC. However, the severity seems to have a notable variability in TSC patients. Risk factors for ASD are
epilepsy, infantile spams, and mutations in TSC2.
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Background
Tuberous Sclerosis Complex (TSC) is a rare disorder as-
sociated with multiorgan involvement, including the
brain, kidneys, heart, lung, skin and eyes. Patients may
also be affected by behavioral, intellectual, psychiatric
and psychosocial difficulties, which often represent the
greatest burden of this disease, for both families and
physicians. The Neuropsychiatric Panel at the 2012
International Tuberous Sclerosis Complex Consensus
Conference adopted the umbrella term TAND (TSC-as-
sociated neuropsychiatric disorders) to describe these is-
sues [1]. Recently, a specific screening tool (the TAND
Checklist) has been developed in order to raise aware-
ness of these problems, which can affect 90 % of patients
[2].
Among the psychiatric problems associated with TSC,
autism spectrum disorder (ASD) is the most common,
affecting up to 61 % of patients [3]. However, its severity
is not frequently reported, and the risk factors for ASD
in the TSC population are still controversial. Epilepsy is
one of the major issues in TSC [4] and is considered a
potential risk factor for ASD in TSC patients, especially
when epilepsy starts early and with infantile spasms.
Several reports have indicated infantile spasms as risk
factors for developing autism in children with TSC [5,
6]. However, infantile spasms are not a sufficient cause
of ADS, suggesting that a common neurobiological
mechanism can lead to both infantile spasms and ASD
[7]. The localization of cortical tubers was identified as
another risk factor for developing ASD in TSC patients:
both frontal and temporal tubers were associated with
ASD, and cyst-like cortical tubers were more common
in patients with TSC and ASD [8]. Finally, intellectual
disability (ID) is considered another risk factor for ASD
in patients with TSC [5, 9]. Interestingly, correlations be-
tween ASD and genotype are emerging, and TSC2 muta-
tions seem to be more frequently associated with ASD,
regardless the mutation type [8].
Overall, knowledge about the characteristics of ASD as
an endophenotype in TSC needs to be improved, and a
reliable and valid assessment is needed in this popula-
tion [3]. For these reasons, the aims of this study were:
1) to assess the prevalence of ASD in a TSC population;
2) to describe the severity of ASD; 3) to identify poten-




We selected 42 individuals with a definite diagnosis
of TSC [10] among 113 patients who underwent a
follow-up visit in the TSC clinic at San Paolo Univer-
sity Hospital in Milan, Italy, between September 2013
and July 2014. According to the inclusion criteria, the
patients had to be at least 4 years old and have a
mental age over 2 years. Patients over 18 years were
included only if they resulted to be dependent on a
caregiver.
Seventy-one patients were excluded as they did not
meet the inclusion criteria: ten were under age four, 18
showed profound ID with a mental age under 2 years,
41 were adults not dependent on a caregiver, for two in-
dividuals the caregiver was not present at the time of the
visit. Nobody declined to participate in the study.
All the patients included in this study underwent a
cognitive and communication skills/social functioning
evaluation. We collected data on each patient’s clinical
history, epilepsy, and genetic tests as well.
Informed consent was obtained, and this study was ap-
proved by the IRB of our institution.
Cognitive evaluation
Cognitive level was assessed using the following tests,
based on the patient’s age and the test’s applicability:
– Griffiths scale and Wechsler scale (Wechsler
preschool and primary scale of intelligence, revised,
WPPSI-R) for patients aged 3 to 6 years;
– Wechsler scale (Wechsler intelligence scale for
children, Third edition WISC-III) and Raven’s col-
ored progressive matrices for patients aged 6 to
12 years;
– Wechsler scale (WISC-III, Wechsler Adult
Intelligence Scale, revised, WAIS-R), Leiter-R scale,
and Raven’s colored progressive matrices for patients
aged 13 to 18 years;
– Wechsler scale (WAIS-R) for adult patients when
possible, and Raven’s standard progressive matrices
in one case.
Cognitive level was evaluated clinically when a formal
test could not be performed due to severely impaired
mental status, according to the international statistical
classification of diseases and related health problems,
tenth revision (ICD-10) [11].
Communication skills and social functioning evaluation
We used the Social Communication Questionnaire
(SCQ), lifetime form, Italian translation [12], in order
to evaluate communication skills and social function-
ing of each patient, as a quick and reliable screening
tool for ASD [13]. The questionnaire is composed of
40 yes/no questions adapted from the Autism Diag-
nostic Interview (ADI-R). Most of the questions cor-
respond to the three main ADI domains: 1.
Reciprocal social interaction; 2. Language/communica-
tion; 3. Restricted, repetitive, and stereotyped behav-
iors and interests. According to the instructions, the
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SCQ was completed by the parents/caregivers. Al-
though it could be filled in autonomously, we chose
to let caregivers complete it in the presence of a
physician or psychologist since clinical experience has
shown this method leads to more accurate results. A
clinical cut-off of 15 points or more is suggestive of
ASD, with a sensitivity of 0.85, a specificity of 0.75,
positive predictive value of 0.93, and negative predict-
ive value of 0.55 when differentiating ASD from other
diagnoses [14]. A score of 22 points or higher is sug-
gestive of autism (AD), differentiating it from other
forms of ASD [15]. A team of child neurologists with
wide expertise in ASD evaluated clinically all the pa-
tients. The diagnosis of ASD/AD was confirmed or
excluded clinically according to the DSM-IV-TR cri-
teria. Quality of the social interactions (social over-
tures, social response, shared enjoyment in
interaction, unusual eye contact, facial expressions, fa-
cial expressions, reciprocal smiling at others, giving,
showing, spontaneous initiation of joint attention),
communicative behaviors (pointing, gestures, use of
other’s body to communicate) and stereotyped behav-
ior and restricted interests (unusually repetitive and
stereotyped behaviors, unusual sensory interest in play
material/person, hand and finger mannerisms, other
complex mannerisms or stereotyped body movements)
were evaluated.
Statistical analysis
Data on the 42 patients were transferred into an elec-
tronic database and processed using the Statistical
Package for the Social Sciences (SPSS, IBM, Chicago,
IL, U.S.A.) for Macintosh, version 21.0. Continuous
variables were presented as mean and standard devi-
ation (SD). We performed comparisons between the
average SCQ scores for each clinical and genetic fea-
ture, using χ2 test (categorized variables not normally
distributed), independent sample two tailed Student
(t-tests, variables with a normal distribution) and one-
way analyses of variance (ANOVA) with Bonferroni
post hoc as appropriate.
We chose a two-tailed p value of 0.05 or less to define
statistically significant results.
Results
We analyzed 42 patients with a definite diagnosis of
TSC. This cohort was composed of 24 females (57.1 %)
and 18 males (42.9 %), aged 4 to 44 years, with a median
age of 19.3 years. Twenty-three of them (54.8 %) were
adults and 19 (45.2 %) were children under 18 years of
age. With respect to genetic analyses, 10 patients
(23.8 %) had a mutation in TSC1, 30 (71.4 %) a mutation
in TSC2, and in two patients (4.8 %) no mutations in
either gene could be identified by current diagnostic
methods (NMI).
The prevalence of cortical tubers, subependimal nod-
ules (SENs), subependimal giant cell astrocytomas
(SEGAs), sleep disorders, psychiatric symptoms, and epi-
lepsy was assessed, resulting consistent with the data
present in the scientific literature (data not shown).
We were able to measure the cognitive level in 30 out
of 42 patients. The remaining 12 individuals were con-
sidered to be non-testable due to a severely impaired
mental status (10) or poor compliance (2): therefore, a
child neurologist evaluated their cognitive level clinically.
The results are shown in Table 1.
With respect to the SCQ, 17 patients (40.5 %) had
a score of 15 points or higher, and 25 (59.5 %) had a
score lower than 15. The scores were equally distrib-
uted in our sample, as shown in Fig. 1. A comparison
between the score ranges obtained in each of the
three ADI domains in the patients with a score ≥ 15
and in those with a score < 15 is shown in Fig. 2. The
total average score was 10.9 (SD 7.8), ranging 0–26
points. When calculated for each cognitive level cat-
egory, the average SCQ score tended to be progres-
sively higher in patients with a worse cognitive level:
9.8 (±6.7) in patients with mild ID, 11.75 (±8.1) in
patients with moderate ID, and 17.7 (±6.2) in patients
with severe ID (Fig. 3a). All the patients with a nor-
mal or borderline mental status scored less than 15.
The number of pathological SCQ scores (≥15) in-
creased with worsening of intellectual disability as
well (Fig. 3b). By comparing the scores obtained in
the three main domains with the cognitive level, we
found statically significant differences with respect to
social interaction (p = 0.003) and communication (p =
0.007), but not to repetitive behaviors.
In order to better characterize the patients with an
SCQ score suggestive of ASD, we evaluated at first
the demographic, clinical and genetic characteristics
in these patients:
Demographic features
Six were children (35.3 %) and 11 were adults (64.7 %),
aged 6–44 years (median age 21.5 years). The gender
Table 1 Cognitive levels of the population presented in this
study
Cognitive level Number of patients (%)
Normal 5 (11.9 %)
BIF 6 (14.3 %)
Mild ID 9 (21.4 %)
Moderate ID 12 (28.6 %)
Severe ID 10 (23.8 %)
BIF Borderline Intellectual Functioning; ID Intellectual Disability
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distribution was almost equal: 58.8 % females versus
41.2 % males. Only three patients (17.6 %) had a positive
family history of TSC.
Genetics
Fifteen patients (88.2 %) had a mutation in TSC2, two
(11.8 %) had a mutation in TSC1. No NMI patient had a
pathological score. Among the TSC2 patients, 12 had a
protein truncating (PT) mutation, two a non-truncating
(NT) mutation in the GAP domain, and one a proximal
NT mutation but not in the Hamartin Interaction
Domain.
Central nervous system features
All of them but one presented with multiple cortical
tubers; 15 (88.2 %) had SENs; four (23.5 %) developed
Fig. 1 Distribution of SCQ scores. The horizontal axis displays the scores, and the vertical axis shows the number of patients
Fig. 2 Ranges of the scores obtained in each of the three ADI domains in the patients with a score≥ 15 (left) and in those with a score < 15
(right). Blue: restricted, repetitive, and stereotyped behaviors and interests. Green: reciprocal social interaction. Red: language/communication
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a SEGA. With respect to tubers localization, there
was not a prevalence of a lobe to the others.
Epilepsy
Seizures were present in all the patients: mean age at on-
set was 7.9 months (birth to 18 months), with the major-
ity of patients having a positive history for infantile
spasms (11 patients, 64.7 %), and still having seizures at
the time of the evaluation (11 patients, 64.7 %). Most of
them were on multiple antiepileptic drugs (11 patients,
64.7 %). EEG was normal in three patients (17.6 %),
while it showed focal activity in 12 (70.6 %), and a slow
background activity in seven (41.2 %).
Sleep disorders
Seven patients (41.2 %) presented with a sleep disorder.
Psychiatric diseases
Ten patients (58.8 %) showed psychiatric symptoms
(OCD, anxiety, psychosis, mood changes) or behavioral
anomalies (hyperactivity, aggressive behavior).
Since the SCQ provides a quantitative measurement of
symptom severity, we examined the total scores for each
patient with a pathologic SCQ. The scores ranged from
15 to 26 points, with the most represented ones being
15 (four patients), 18 (four patients), and 22 (three pa-
tients), and the other scores being equally distributed.
Six out of 17 patients (35 %) scored 22 points or higher.
Fig. 3 A:SCQ scores in relation to cognitive level. Note how the score progressively increases with worsening of mental status. B: Proportion between
normal (<15) and pathological (≥15) SCQ scores according to cognitive level. Green rectangles indicate normal scores, and red rectangles indicate
pathological scores. BIF: Borderline Intellectual Functioning. ID: Intellectual Disability
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In all of them we confirmed a diagnosis of autism clinic-
ally, according to the DSM-IV-TR criteria. We also ex-
cluded the diagnosis of ASD in all the individuals with
SCQ scores less than 15 after clinical evaluation by an
expert.
Finally, we considered the clinical and genetics charac-
teristics of all the 42 patients, calculated the average
SCQ score for each of them, and compared the scores
for each variable in order to look for possible risk factors
for ASD. The results are shown in Tables 2 and 3.
Discussion
TSC is a complex genetic disease with multiple difficul-
ties. Neurobehavioral problems often represent the
Table 2 Comparison between the average SCQ scores for each clinical and genetic feature
Gender Male Female
Number of patients 18 (42.8 %) 24 (57.1 %) NS
Average SCQ score ±SD 10.6 ± 7.0 11.2 ± 8.5
Mutation TSC1 TSC2 NMI
Number of patients 10 (23.8 %) 30 (71.4 %) 2 (4.8 %)
Average SCQ score ±SD 6.3 ± 6.0 12.6 ± 8.0 9.5 ± 3.5 NS
p<0.03*
6.3 ± 6.0 12.6 ± 8.0
Epilepsy Present Absent
Number of patients 36 (85.7 %) 6 (14.3 %)
Average SCQ score ±SD 12.1 ±7.7 4.2 ± 4.7 p<0.05*
Onset of seizures Before age 12 months After age 12 months
Number of patients 25 (69.4 %) 11 (30.6 %)
Average SCQ score ±SD 14.0 ± 7.4 7.5 ± 6.4 p<0.05*
Spasms Present Absent
Number of patients 18 (50 %) 18 (50 %)
Average SCQ score ±SD 15.1 ±7.4 8.2 ± 6.6 p<0.05*
AEDs (at time of evaluation) Monotherapy Polytherapy
Number of patients 13 (39.4 %) 20 (60.6 %)
Average SCQ score ±SD 10.1 ± 9.0 13.6 ± 6.3 NS
Seizure frequency None Monthly Weekly
Number of patients 19 (52.8 %) 7 (19.4 %) 10 (27.8 %)
Average SCQ score ±SD 9.9 ± 8.0 15.7 ± 5.3 13.6 ± 7.8 NS
IQ IQ≥70 IQ<70
Number of patients 11 (36.7 %) 19 (63.3 %)
Average SCQ score ±SD 4.8 ± 4.3 11.5 ±6.7 p<0.05*
Sleep disorders Present Absent
Number of patients 9 (21.4 %) 33 (78.6 %)
Average SCQ score ±SD 16.4 ± 8.0 9.4 ± 7.1 p<0.05*
Psychiatric disorders Present Absent
Number of patients 17 (41.5 %) 24 (58.5 %)
Average SCQ score ±SD 13.3 ± 8.7 8.6 ± 6.0 p<0.05*
Statistically significant findings are written in bold
NS not statistically significant; AEDs antiepileptic drugs
Table 3 This table shows the number of patients with TSC1 and
TSC2 mutations for each group (pathologic and non-pathologic
SCQ score)
TSC and SCQ≥15 TSC and SCQ<15 p value
TSC1 2 8 0.05
TSC2 15 15 1.00
NMI 0 2 not performed
total 17 25
Note that TSC1 patients have statistically significant less frequency of
pathologic SCQ
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major issue in affected individuals and their families. Pa-
tients with TSC should undergo a comprehensive pheno-
typic evaluation throughout measures of neural activity
(EEG), detection of subtle structural abnormalities
(MRI), and appropriate behavioral assessment [3].
Besides the application of structured screening tools,
such as the TAND checklist [2], deeper insight for spe-
cific neuropsychiatric disabilities should be implemented
in the TSC population. Recently, Granader et al. [14] ap-
plied the Social Communication Questionnaire (SCQ) in
a cohort of 21 children with TSC and searched for rela-
tionships between SCQ measures and cognitive develop-
ment. The authors found ASD in 52 % of the patients,
which correlated with intellectual functioning and AEDs
number. We applied the same tool in our population.
The use of the SCQ allowed us to identify patients with
ASD symptomatology and to better characterize the se-
verity of the psychiatric symptomatology. Furthermore,
we correlated the SCQ scores with clinical features that
could be implicated in disease modification.
The rate of ASD in TSC varies widely in published re-
ports (from 17 % to 63 %). In our group of patients SCQ
scores suggestive of ASD were found in 40.5 %, in line
with recent literature data [8]. We also confirmed that in
patients with TSC there is no gender difference for ASD
[16]. A major limit of this study is that we couldn’t per-
form ADI/ADOS in all patients, currently considered
the gold standard for the diagnosis of ASD [17]. How-
ever, all the diagnoses were confirmed by direct clinical
observation, and we found no false positive and false
negative results in our cohort, possibly due to the rela-
tively small sample size. Therefore, although the SCQ
should be considered a screening and not a diagnostic
tool for ASD, it proved to be a reliable means for dis-
criminating between patients with and without ASD in
our sample.
With respect to ASD severity, the higher score on
SCQ, the higher the likelihood that the child exhibits in-
creased ASD symptomatology [18]. The scores were
equally distributed in our sample, indicating that the de-
gree of ASD in TSC patients may have a large variability.
Also the clinical observation of these patients confirmed
the absence of a uniform degree of severity. Interest-
ingly, a narrow diagnosis of autism was identified in
35 % of patients. Furthermore, we found that patients
with ASD were significantly different from patients with-
out ASD with respect to the reciprocal social interaction
domain and to the language/communication domain,
while the restricted, repetitive, and stereotyped behaviors
and interests domain did not reach significance between
the two groups. In our experience we rarely noticed ste-
reotypies and repetitive behaviors in these patients in-
deed, suggesting that in TSC patients with ASD this area
might be less compromised than the others. However,
further studies including a larger number of patients and
using diagnostic tools for autism should be performed to
better clarify this finding.
Regarding risk factors for ASD, epilepsy certainly plays
a major role, since all the patients with ASD had epi-
lepsy, and mean age of seizure onset was significantly
lower in patients with ASD compared to patients with-
out ASD (7.9 months vs 16.9 months). This finding fur-
ther supports the association between epileptic activity
and specific aspects of brain development, such as social
intelligence and other cognitive skills involved in the
pathophysiology of ASD [7].
Impaired neural connectivity rather than a localized
deficit has been demonstrated to be responsible for the
pathophysiological process of ASD [19]. This applies also
to TSC patients, in which aberrant connectivity was
demonstrated in normal-appearing perituberal cortex
[20]. As a consequence of this new interpretation of the
TSC brain, the role of tubers’ number and localization
should be reconsidered. Interestingly, we couldn’t find
any association between tubers localization and the SCQ
score. In particular, patients with a pathologic SCQ score
presented with frontal and temporal tubers as well as
parietal and occipital, and temporal and parietal tubers
were present in both patients with and without ASD.
Among the patients with a pathological SCQ score,
those with seizure onset within the first year of life had
the most severe signs of ASD, especially when epilepsy
started with infantile spasms, thus confirming previous
studies.
Early recognition of subtle focal seizures and infantile
spasms, obtained throughout parental education and
close EEG monitoring, allows prompt seizure control
and can prevent epileptic encephalopathy and subse-
quent long-term cognitive and behavioral consequences,
especially autism [21, 22]. Existing data are insufficient
to support preventive therapy in infants with TSC with-
out documented seizures, unless subclinical seizures are
recorded [22]. The relationship between epileptic spasms
and ASD has been recently supported by animal models,
where Tsc2 haploinsufficiency and developmental status
epilepticus in Tsc2+/− rats independently lead to social
interaction deficits, suggesting the additive effect of sei-
zures to increase the range of autistic-like behaviors in
mutated animals [23].
A relationship between specific mutation types in pa-
tients with TSC and neurodevelopmental outcome is still
debated. Numis et al. [8] found a higher prevalence of
ASD in individuals carrying TSC2 mutations, but they
did not observe a significant association between ASD
and mutation type in the TSC2 gene. Also in our study
the great majority of patients with ASD had a mutation
in TSC2 (88.2 %), 11.8 % had a mutation in TSC1, while
no NMI patient had a pathological score. Furthermore,
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our results showed that TSC1 patients have less often a
pathologic SCQ score (p = 0.05), while no difference was
found in TSC2 patients. Recently, Huang et al. [24]
found a relationship between ASD and nonsense muta-
tions in the TSC2 gene in a small group. Among our pa-
tients with truncating mutations, 12 had a pathologic
SCQ score and 11 a normal score, so we couldn’t con-
firm that finding. In general, it was not possible to find a
correlation between mutation subtypes and SCQ score,
probably also due to the small sample size.
Cognitive level appeared to be strictly correlated with
the average SCQ score, which tended to be progressively
higher in patients with a worse ID. Furthermore, all the
patients with a normal or borderline mental status didn’t
have ASD. This data cannot be attributed to the tool it-
self because SCQ demonstrated a good specificity in
diagnosing ASD independently of ID [13]. The linear re-
lationship between ID and ASD emerging from our
study has been recently demonstrated also by Van
Eeghen et al. [9], but referring to Social Responsiveness.
Moreover, it is very important to identify ASD in pa-
tients with ID because rehabilitation strategies can be
modified and targeted according to the individual’s
needs.
With respect to other neuro-psychiatric variables in
TSC patients with ASD, we found a higher prevalence of
sleep disorders, psychiatric symptoms and behavioral
problems. Regarding sleep disorders in TSC, this issue
has been poorly investigated [25, 26]. A sleep disorder
has been reported in 30 % of patients with TSC, mainly
insomnia, which showed a significant positive correl-
ation with obstructive sleep apnea syndrome and restless
legs scores [27].
Even though a higher prevalence of psychiatric symp-
toms in TSC patients rather than in general population is
well known, few studies focused on this topic. The most
frequently encountered formal diagnoses were anxiety dis-
orders, mood disorders, adjustment disorders, ADHD and
metal disorders not otherwise specified [2, 28]. Moreover,
recent research focused on the possibility of recognizing a
series of psychiatric symptoms, which can go along with
the ASD core, such as self-injury, aggressiveness, stereo-
typed behaviors, and insistence on sameness [29–31].
With our study we confirm that psychiatric comorbidity is
very common in patients with TSC, and should be man-
aged with appropriate pharmacologic therapy in affected
individuals.
Although our study is limited to 42 patients, it repre-
sents the largest cohort of TSC subjects assessed using
the SCQ. Furthermore, we were able to precisely
characterize the sample with respect to cognitive func-
tioning and molecular genetics.
The patients’ selection due to the applicability of the
SCQ could certainly represent a bias of the study, since
a fairly high number of subjects with profound ID and
adults not dependent on a caregiver were excluded.
However, the selected patients underwent a solid clinical
evaluation apart from the questionnaire.
Conclusion
This study showed a prevalence of ASD of 40.5 %, con-
firming that patients with TSC have a high risk for this
disorder. Early recognition of patients developing ASD
symptomatology can bring them to early behavioral
intervention focused on specific signs, and can address
the need of global care requested by the families. The se-
verity of ASD seems to have a notable variability in TSC
patients. Risk factors for ASD in these patients are epi-
lepsy, infantile spams, and mutations in TSC2, while the
localization of tubers is not correlated to it.
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